Literature DB >> 16185156

Targeting the Fas/Fas ligand pathway in cancer.

Darren I O'Brien1, Ken Nally, Raymond G Kelly, Terrence M O'Connor, Fergus Shanahan, Joe O'Connell.   

Abstract

Fas is a transmembrane receptor that can induce apoptosis after cross-linking with either agonistic antibodies or with Fas ligand (FasL). Although originally described as an important regulator of peripheral immune homeostasis, accumulating evidence suggests that the Fas/FasL system plays an important role in tumour development. In addition to its proapoptotic functions, accumulating evidence demonstrates that Fas can activate numerous nonapoptotic signalling pathways, and that activation of these pathways can result in increased tumourigenicity and metastasis. This review summarises the current understanding of the Fas/FasL system in tumorigenesis and discusses attempts to utilise the Fas/FasL system in the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16185156     DOI: 10.1517/14728222.9.5.1031

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  16 in total

1.  Platelet-RBC interaction mediated by FasL/FasR induces procoagulant activity important for thrombosis.

Authors:  Christoph Klatt; Irena Krüger; Saskia Zey; Kim-Jürgen Krott; Martina Spelleken; Nina Sarah Gowert; Alexander Oberhuber; Lena Pfaff; Wiebke Lückstädt; Kerstin Jurk; Martin Schaller; Hadi Al-Hasani; Jürgen Schrader; Steffen Massberg; Konstantin Stark; Hubert Schelzig; Malte Kelm; Margitta Elvers
Journal:  J Clin Invest       Date:  2018-08-13       Impact factor: 14.808

2.  A primate-specific POTE-actin fusion protein plays a role in apoptosis.

Authors:  Xiu Fen Liu; Tapan K Bera; Lisa J Liu; Ira Pastan
Journal:  Apoptosis       Date:  2009-10       Impact factor: 4.677

3.  Clinical implications of Fas/Fas ligand expression in patients with esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy.

Authors:  Susumu Saigusa; Koji Tanaka; Masaki Ohi; Yuji Toiyama; Hiromi Yasuda; Takahito Kitajima; Yoshinaga Okugawa; Yasuhiro Inoue; Yasuhiko Mohri; Masato Kusunoki
Journal:  Mol Clin Oncol       Date:  2014-09-26

4.  Cytoplasmic overexpression of CD95L in esophageal adenocarcinoma cells overcomes resistance to CD95-mediated apoptosis.

Authors:  Gregory A Watson; Sanjay Naran; Xinglu Zhang; Michael T Stang; Pierre E Queiroz de Oliveira; Steven J Hughes
Journal:  Neoplasia       Date:  2011-03       Impact factor: 5.715

5.  Serum markers of apoptosis decrease with age and cancer stage.

Authors:  Nilay Kavathia; Alka Jain; Jeremy Walston; Brock A Beamer; Neal S Fedarko
Journal:  Aging (Albany NY)       Date:  2009-07-14       Impact factor: 5.682

6.  (-)-Epigallocatechin-3-gallate (EGCG) sensitizes melanoma cells to interferon induced growth inhibition in a mouse model of human melanoma.

Authors:  Minakshi Nihal; Haseeb Ahsan; Imtiaz A Siddiqui; Hasan Mukhtar; Nihal Ahmad; Gary S Wood
Journal:  Cell Cycle       Date:  2009-07-27       Impact factor: 4.534

Review 7.  Cancer-Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery.

Authors:  Hannah J Vaughan; Jordan J Green; Stephany Y Tzeng
Journal:  Adv Mater       Date:  2019-06-20       Impact factor: 30.849

8.  Functional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases.

Authors:  Mohammad Hashemi; Aliakbar Fazaeli; Saeid Ghavami; Ebrahim Eskandari-Nasab; Farshid Arbabi; Mohammad Ali Mashhadi; Mohsen Taheri; Wiem Chaabane; Mayur V Jain; Marek J Łos
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

Review 9.  Exosomes as mediators of immune regulation and immunotherapy in cancer.

Authors:  Fernanda G Kugeratski; Raghu Kalluri
Journal:  FEBS J       Date:  2020-10-03       Impact factor: 5.622

10.  A common hereditary single-nucleotide polymorphism in the gene of FAS and colorectal cancer survival.

Authors:  Guenter Hofmann; Uwe Langsenlehner; Tanja Langsenlehner; Babak Yazdani-Biuki; Heimo Clar; Armin Gerger; Florentine Fuerst; Hellmut Samonigg; Peter Krippl; Wilfried Renner
Journal:  J Cell Mol Med       Date:  2009-02-27       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.